CAMBRIDGE, Mass., Oct. 14, 2016 /PRNewswire/ -- Today, Good Start Genetics announced its plans to present data from three scientific studies focused on preimplantation genetic screening (PGS) at the annual meeting of the American Society for Reproductive Medicine (ASRM). These studies cover new research using EmbryVu®, the company's PGS test, developed to detect chromosome abnormalities in embryos created through in vitro fertilization (IVF). This information can be used to select healthy embryos for transfer leading to an increase in IVF success. The test uses the company's own proprietary next-generation sequencing (NGS) platform and technology exclusively licensed from Johns Hopkins University, enabling Good Start Genetics to offer EmbryVu at considerably lower prices than other PGS tests currently on the market. The Company's low cost of testing enables more patients to access high-quality technology to help improve their chances of pregnancy. The data will be presented by Greg Porreca, Founder and Chief Technology Officer, and his team and will cover the validation of the assay and clinical experience.
Good Start Genetics will present the following abstracts:
"Accurate Detection of Segmental Aneuploidy in Preimplantation Genetic Screening Using Targeted Next-Generation DNA Sequencing" — This presentation will cover Good Start Genetics' validation of its NGS-based PGS ability to detect segmental aneuploidy. Using a combination of cell-line derived samples and simulations, Good Start Genetics was able to conclude that in addition to whole chromosome abnormalities, EmbryVu can accurately detect segmental aneuploidies of 10 Mb or greater across the genome.
"Segmental Aneuploidy in Preimplantation Genetic Screening Stratified by Age and Clinical Indication Using Targeted Next-Generation DNA Sequencing" — This presentation will summarize Good Start Genetics' clinical experience in detecting segmental aneuploidy using their NGS-based PGS assay. The study found that segmental aneuploidies were seen in both embryos with and without additional whole chromosome aneuploidies and that segmental aneuploidy rates were similar across all age groups. These findings are similar to published rates using other technologies.
"Clinical Experience With a Targeted NGS-based Preimplantation Genetic Screening Assay" — This presentation will summarize Good Start Genetics' clinical experience in detecting whole chromosome aneuploidy using their NGS-based PGS assay. Observed aneuploidy rates were dependent on egg age and are in line with published rates using other technologies.
About Good Start Genetics
Good Start Genetics is an information solutions company delivering best-in-class genetics offerings to growing families. Using advanced clinical sequencing, proprietary methods and information tailored to the individual, the Company's suite of offerings arms clinicians and patients with insightful and actionable information to promote successful pregnancies and help build healthy families. The newly launched VeriYou broadens the Company's product portfolio to deliver carrier screening to families of all economic backgrounds. Its flagship genetic carrier screening service, GeneVu, is a comprehensive menu of highly-accurate tests for known and novel mutations that cause inherited genetic disorders, and its proprietary and advanced preimplantation genetic screening test, EmbryVu, based on technologies exclusively licensed from Johns Hopkins University School of Medicine, is helping a wider range of couples find their paths to pregnancy at significantly lower costs. Good Start Genetics complements these offerings with world class customer care and genetic counseling to help families stay well-informed and best prepare for tomorrow. For more information, please visit www.goodstartgenetics.com or join us on Facebook, Twitter and LinkedIn.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/good-start-genetics-to-present-new-in-vitro-fertilization-scientific-findings-at-the-american-society-of-reproductive-medicine-conference-300344972.html
SOURCE Good Start Genetics, Inc.